Latest News

Latest News

An AI Study Without Its Data Is Fiction

An AI Study Without Its Data Is Fiction

Why publish the data at all? My answer comes from my own work. We ran our study not with one AI agent but with several, and later it turned out that the numbers did not match. Without validated AI study data, data that the author answers for in front of the scientific...

read more
Weekly News Roundup | 19 October 2026

Weekly News Roundup | 19 October 2026

Life science news 19 October 2026: three licensing deals, three FDA approvals and two MHRA announcements. Gilead Sciences signed a T-cell engager deal worth up to $1.875bn with Vir Biotechnology. Roche licensed an ALK7 obesity candidate from Rona Therapeutics. The...

read more
Clinical Trial Results 16 October 2026

Clinical Trial Results 16 October 2026

The clinical trial results 16 October 2026 cover neuroendocrine tumours, bladder, head and neck cancers, pulmonary fibrosis and social anxiety. RayzeBio’s RYZ101 met its primary endpoint at interim analysis in gastroenteropancreatic neuroendocrine tumours. The FDA...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Ziltivekimab ZEUS Trial: What the Null Result Means

Ziltivekimab ZEUS Trial: What the Null Result Means

The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...

read more
Singapore Radiopharmaceutical Market: How H2 2026 Looks

Singapore Radiopharmaceutical Market: How H2 2026 Looks

The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...

read more
Why True Health Foods Need Evidence, Not Fashion

Why True Health Foods Need Evidence, Not Fashion

Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...

read more
Weekly News Roundup | 03 August 2026

Weekly News Roundup | 03 August 2026

Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings...

read more
Ziltivekimab ZEUS Trial: What the Null Result Means

Ziltivekimab ZEUS Trial: What the Null Result Means

The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...

read more
Singapore Radiopharmaceutical Market: How H2 2026 Looks

Singapore Radiopharmaceutical Market: How H2 2026 Looks

The Singapore radiopharmaceutical market enters the second half of 2026 with more clinical capacity, more research output and a heavier regulatory calendar than at any previous point. New imaging infrastructure came online at the end of 2025, first-in-human data from...

read more
Why True Health Foods Need Evidence, Not Fashion

Why True Health Foods Need Evidence, Not Fashion

Functional foods have entered the mainstream, but adding a recognised ingredient is not the same as creating a credible product. A cardiologist argues that the category’s next phase will be won on scientific rationale, dose and honest communication, not on the length...

read more
Weekly News Roundup | 03 August 2026

Weekly News Roundup | 03 August 2026

Life science news 3 August 2026: argenx pays $2.2 billion for what it calls a first-in-class anti-CD122 antibody, Johnson & Johnson strikes agreements worth up to $3.5 billion with in vivo CAR-T developer Sail Biomedicines, and GSK launches a £1.9 billion savings...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

FDA Drug Approval Decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...

read more
Clinical Trials Roundup | 31 July 2026

Clinical Trials Roundup | 31 July 2026

An FDA advisory committee votes against Capricor Therapeutics' deramiocel in Duchenne muscular dystrophy cardiomyopathy, Pfizer's ritlecitinib meets its co-primary endpoints in two Phase 3 nonsegmental vitiligo trials, Karyopharm Therapeutics' selinexor misses its...

read more
The Security Blind Spot in Life Science Digitalization

The Security Blind Spot in Life Science Digitalization

The life sciences sector is in the midst of a digital transformation that most security teams were not built to handle. AI-driven drug discovery platforms, cloud-connected lab equipment, genomic databases, and real-time patient data pipelines are creating attack...

read more
Making AI Work in a Regulated Medtech Industry

Making AI Work in a Regulated Medtech Industry

For several years, AI has been viewed as one of the biggest opportunities for the medtech sector. With an industry survey finding that 91% of leaders were enthusiastic about its potential, early conversations centred on how it could transform healthcare delivery and...

read more
Biotech IPO 2026: From Drought to Record-Breaking Deals

Biotech IPO 2026: From Drought to Record-Breaking Deals

The first half of 2026 has delivered a decisive answer to a question the life sciences industry has been asking for years: is the biotech IPO window finally open again? The drought bottomed out in 2025, when fewer biotechs went public than in any year in at least half...

read more
Want the FDA to Make Peptides More Accessible?

Want the FDA to Make Peptides More Accessible?

As the FDA considers reclassifying seven popular peptides, experts say the decision could change how patients access these compounds. As the FDA evaluates whether several commonly used peptides should become eligible for pharmacy compounding, the outcome could...

read more
Psychedelic Medicine Commercialization: Altered Perceptions

Psychedelic Medicine Commercialization: Altered Perceptions

Lilly’s acquisition of AtaiBeckley validates the therapeutic and economic promise of rapid-acting neuroplastogens. It also raises a harder question: can commercial teams redesign the beliefs surrounding these medicines as effectively as scientists are redesigning the...

read more

Further News

Surgical Site Infections Can Consume Up to 75 Staff Hours

Surgical site infections can consume up to 75 staff hours and displace three operations, research finds A single surgical site infection (SSI) can consume an estimated 45 to 75 additional hours of healthcare staff time and create downstream demands equivalent to the...

Amylin Analogues Explained: The Next Obesity Drug Battleground

Amylin analogues have become one of the most active areas of obesity drug development. Novo Nordisk, Eli Lilly, Roche, Pfizer, AbbVie and AstraZeneca all hold clinical programmes built on the hormone amylin. The most advanced obesity candidate in the class, Novo...

The New Launch Model for the Agentic Era

Creating brand value when clinical information is no longer a differentiator The Life Sciences industry is undergoing seismic shifts: expanding drug pipelines, compressed launch timelines, and changing healthcare provider (HCP) and human capital expectations. HCPs...

Britain’s Nicotine Pouch Problem: What It Means for Oral Health

The UK Government has taken steps to combat smoking, and now nicotine pouches, through legislation, public health campaigns, youth prevention and support services. In the UK the age limit for smoking is 18 years old, meaning that individuals must be at least 18 to buy...

FUS-ALS Treatment Clears Phase 3 but the Figures Stay Unpublished

Ionis Pharmaceuticals and Otsuka Pharmaceutical reported positive topline results on 22 September 2026 from the Phase 3 FUSION study. The trial tested ulefnersen in amyotrophic lateral sclerosis caused by mutations in the fused in sarcoma gene. Ionis describes the...

Why Business Fundamentals Belong in Every Life Sciences Career

As a life scientist you might not have considered a business education. You are good at what you do, you may have no ambition to run a company or sit at a boardroom table. So why spend time on business fundamentals? The honest answer is that deep technical expertise...

Telix Buys ITM: Radioisotope Supply and a Manufacturing Test

Telix will pay US$1.65bn for ITM, placing the sector’s largest radioisotope supply business inside a developer whose rivals depend on it.

    LNP Engineering for RNA Delivery: Beyond Encapsulation Efficiency

    For RNA therapeutics, encapsulation efficiency is a formulation metric—not proof of functional delivery. The development of lipid nanoparticle (LNP) RNA delivery systems is entering a more demanding phase. As nucleic acid therapeutics expand beyond conventional siRNA...

    Closing the Gap: Why Where You Live Still Determines Your IBD Care

    Inflammatory bowel disease (IBD) is no longer a rare disease in Australia. Close to 180,000 Australians are now living with Crohn’s disease or ulcerative colitis, with prevalence approaching 1% of the population in some estimates. Unlike many chronic diseases, IBD...

    How GLP-1 Drugs Are Reshaping Anesthesia Practice

    Few classes of medications have changed the perioperative conversation as quickly as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Originally developed primarily for the management of type 2 diabetes, GLP-1 therapy is now widely used for obesity and metabolic...

    Designing Resilient Health Systems That Endure

    The most resilient health systems are not the ones that respond best in times of disruption, they’re the ones designed so that when disruption occurs, care continues and communities remain protected. Systems continue to struggle with workforce shortages, delayed care,...

    Weekly News Roundup | 21 September 2026

    Life science news 21 September 2026: first US Sanfilippo approval, DESTINY-Lung04 data and a NICE OCD consultation. The FDA approved Fayuvi, the first treatment for Sanfilippo syndrome type A. AstraZeneca and Daiichi Sankyo’s Enhertu cut the risk of lung cancer...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.